Intranasal COVID-19 vaccine: a modern vaccination approach

Shahnoor, Syeda; Priya, Priya; Khatri, Govinda

doi:10.1097/js9.0000000000000046

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, intramuscular injection is a major route of vaccination that induces systemic cellular immune memory and humoral immunity 99 . Alternatively, as a subgroup of the mucosal delivery system, intranasal vaccination may induce both localised mucosal protection and systemic immune responses by boosting mucosal immunoglobulins and cellular immune responses in the respiratory tract 100 . In the current respiratory disease epidemic in China, it is recommended that people over 6 months of age without contraindications actively vaccinate related vaccines as they can get mainly according to the characteristics of vaccines, disease prevention and control needs to decide, especially “one old and one young”, and the main types of vaccines to prevent respiratory diseases include inactivated/live-attenuated influenza virus vaccine, COVID-19 vaccine, pneumococcal polysaccharide vaccine, and haemophilus influenzae type b vaccine.…”

Section: Current Circulating Respiratory Pathogens In Chinamentioning

confidence: 99%

Respiratory pathogenic microbial infections: a narrative review

Long,

Zheng,

et al. 2024

Int. J. Med. Sci.

View full text Add to dashboard Cite

Respiratory infectious diseases have long been recognised as a substantial global healthcare burden and are one of the leading causes of death worldwide, particularly in vulnerable individuals. In the post COVID-19 era, there has been a surge in the prevalence of influenza virus A and other multiple known viruses causing cold compared with during the same period in the previous three years, which coincided with countries easing COVID-19 restrictions worldwide. This article aims to review community-acquired respiratory illnesses covering a broad spectrum of viruses, bacteria, and atypical microorganisms and focuses on the cluster prevalence of multiple known respiratory pathogens in China, thereby providing effective prevention and control measures.

show abstract

Section: Current Circulating Respiratory Pathogens In Chinamentioning

confidence: 99%

Respiratory pathogenic microbial infections: a narrative review

Long,

Zheng,

et al. 2024

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…iNCOVACC has been designed for intranasal administration via nasal drops. The nasal delivery device was created to be affordable in low-and middle-income countries (Shahnoor et al 2023).…”

Section: Introductionmentioning

confidence: 99%

iNCOVACC COVID-19 vaccine: A Twitter based Social Media Analysis Using Natural Language Processing, Sentiment Analysis, and Topic Modelling

Sv¹,

Bhanj²,

Jha³

et al. 2023

J Exp Bio & Ag Sci

View full text Add to dashboard Cite

Most, if not all, the vaccine candidates designed to counteract COVID-19 due to SARS-CoV-2 infection require parenteral administration. Mucosal immunity established by vaccination could significantly contribute to containing the SARS-CoV-2 pandemic, which is spread by infected respiratory secretions. The world has been impacted on many fronts by the COVID-19 pandemic since early 2020 and has yet to recover entirely from the impact of the crisis. In late 2022 and early 2023, China experienced a new surge of COVID-19 outbreaks, mainly in the country's northeastern region. With the threat of new variants like XBB 1.5 and BF.7, India might experience a similar COVID-19 surge as China and needs to be prepared to avoid destruction again. An intranasal vaccine can elicit multiple immunological responses, including IgG neutralization, mucosal IgA production, and T-cell responses. In order to prevent further infection and the spread of COVID-19, local immune responses in the nasal mucosa are required. iNCOVACC is a recombinant vaccine vectored by an adenovirus that contains a SARS-CoV-2 spike protein that has been pre-fusion stabilized. This vaccine candidate has shown promise in both early and late-stage clinical trials. iNCOVACC has been designed for intranasal administration via nasal drops. The nasal delivery system was created to reduce expenses for those living in poor and moderate-income countries. The newly introduced intranasal COVID vaccine will be beneficial in mass immunizing the public as it does not need any syringe and can be proven to be an effective method to boost immunity against the SARS-CoV-2 virus. This study uses natural language processing (NLP) techniques to analyze the Indian citizen's perceptions of the newly developed iNCOVACC vaccine in social media. For this study, we have used social media posts (tweets) as data. We have analyzed 125,300 tweets to study the general perception of Indian citizens regarding the iNCOVACC vaccine. Our results have indicated 43.19% of social media posts discussing the COVID-19 nasal vaccine in a neutral tone, nearly 34.29% of social media posts are positive, and 22.5% of social media posts discussions are negative. The general positive feeling that the iNCOVACC vaccine will work and the risks in the new vaccine are the two significant aspects Indian citizens voice out in social media posts about the iNCOVACC vaccine.

show abstract

Intranasal COVID-19 vaccine: a modern vaccination approach

Cited by 2 publications

References 3 publications

Respiratory pathogenic microbial infections: a narrative review

Respiratory pathogenic microbial infections: a narrative review

iNCOVACC COVID-19 vaccine: A Twitter based Social Media Analysis Using Natural Language Processing, Sentiment Analysis, and Topic Modelling

Contact Info

Product

Resources

About